Effects of stem cell transplantation on bone mineral density and vitamin D status in children with thalassemia major

Gürlek Gökçebay D., Ozbek N., Yazal Erdem A., Culha V., Yarali N. , Isik P., ...More

Pediatric Transplantation, vol.21, no.3, 2017 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.1111/petr.12876
  • Title of Journal : Pediatric Transplantation
  • Keywords: bone mineral density, children, stem cell transplantation, thalassemia major


© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons LtdHSCT is a curative treatment in TM, but conditioning and immunosuppressive treatment may affect bone metabolism. In this retrospective study, we aimed to compare BMD, vitamin D status, and growth in children with TM who underwent HSCT to those in children with TD TM. Twenty-three children with TM who underwent HSCT (mean age 7.1 years [1.03-14.7]) and 24 children with TD thalassemia (mean age 9.8 years [1.6-14]) were recruited. Lumbar spine BMD of TD thalassemia patients was higher than those in patients who had HSCT at both baseline and second-year assessments (P=.009, P<.001, respectively). However, BMD Z scores or serum 25-OH vitamin D levels were not different in two groups. Being >10 years of age was a significant risk factor for low BMD, height, and weight Z score for both groups. Patients who underwent HSCT with Pesaro risk class II or III had higher risk for low BMD compared to those risk class I patients (P=.044). In conclusion, children with TM who were >10 years at HSCT are at risk for low BMD and growth retardation. HSCT had no effect on BMD deficit in children with TM.